Effects of intravenous infusion of hydrogen-rich fluid combined with intra-cisternal infusion of magnesium sulfate in severe aneurysmal subarachnoid hemorrhage: study protocol for a randomized controlled trial.
Satoru Takeuchi, Kentaro Mori, Hirohiko Arimoto, Kazuya Fujii, Kimihiro Nagatani, Satoshi Tomura, Naoki Otani, Hideo Osada, Kojiro Wada · BMC neurology · 2014
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
This publication examined molecular hydrogen using the study design reported by the authoritative source. No study results are reported because this publication is a protocol.
What the Study Plans to Test
The present randomized controlled clinical trial is designed to investigate the effects of this novel therapeutic strategy on the occurrence of cerebral vasospasm, delayed cerebral ischemia, and clinical outcomes after high-grade subarachnoid hemorrhage.
Planned Participants
450 patients with high-grade subarachnoid hemorrhage will be randomized to one of three arms: (i) Mg + H₂ group.
Planned Hydrogen Intervention
Bags of glucose-electrolyte solution (Soldem 1, 200 mL/bag, Terumo, Tokyo, Japan) are immersed, without opening or altering the bag, in a water tank in which water is electrolyzed periodically to produce water with hydrogen concentrations of up to 1.6 ppm. Intravenous hydrogen-rich fluid (200 mL) will be administered at 200 mL/h twice a day (every 12 h).
Current Study Status
This publication describes a planned or ongoing study; H2HUBB presents it as a protocol rather than as completed outcome evidence.